Hatch-Waxman Turns 30: Do We Need a Re-Designed Approach for the Modern Era?
Level 5 - mechanism / opinion, no new human data
Level 5 by design analogy; narrative legal and health policy analysis with expert commentary and no empirical data.
What was done
The authors conducted a legal and policy review assessing the 30-year impact of the 1984 Hatch-Waxman Act, evaluating emerging generic drug market challenges—including deliberate regulatory manipulation and the Supreme Court's 2011 decision in Pliva v. Mensing—and proposing updates to the regulatory framework.
What was found
The authors report that generic drugs account for 84% of all prescriptions dispensed in the United States but comprise less than 20% of total drug costs. The abstract does not provide additional quantitative metrics, focusing instead on qualitative challenges to consumer confidence and timely market entry.
Why it matters
This paper identifies modern legal and structural weaknesses in the foundational generic drug legislation, proposing specific updates to balance cost savings with safety and liability protections.
Limits
The work is a narrative legal commentary lacking empirical testing, quantitative market modeling, or a systematic review design to evaluate the proposed legislative reforms.
Cited by
- context Eighty percent of the approximately 4,000 FDA-approved drugs are already off-patent and available as generic medications.